- Home
- ADGM vs CALC Comparison
ADGM vs CALC Comparison
Compare ADGM & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADGM
- CALC
- Stock Information
- Founded
- ADGM 2011
- CALC 2011
- Country
- ADGM United States
- CALC United States
- Employees
- ADGM N/A
- CALC N/A
- Industry
- ADGM
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- ADGM
- CALC Health Care
- Exchange
- ADGM NYSE
- CALC Nasdaq
- Market Cap
- ADGM 19.7M
- CALC 20.9M
- IPO Year
- ADGM N/A
- CALC N/A
- Fundamental
- Price
- ADGM $1.22
- CALC $1.91
- Analyst Decision
- ADGM
- CALC Strong Buy
- Analyst Count
- ADGM 0
- CALC 3
- Target Price
- ADGM N/A
- CALC $16.33
- AVG Volume (30 Days)
- ADGM 6.1M
- CALC 33.2K
- Earning Date
- ADGM 05-23-2025
- CALC 05-14-2025
- Dividend Yield
- ADGM N/A
- CALC N/A
- EPS Growth
- ADGM N/A
- CALC N/A
- EPS
- ADGM N/A
- CALC N/A
- Revenue
- ADGM $602,000.00
- CALC N/A
- Revenue This Year
- ADGM N/A
- CALC N/A
- Revenue Next Year
- ADGM N/A
- CALC N/A
- P/E Ratio
- ADGM N/A
- CALC N/A
- Revenue Growth
- ADGM 100.67
- CALC N/A
- 52 Week Low
- ADGM $0.63
- CALC $1.43
- 52 Week High
- ADGM $9.34
- CALC $6.02
- Technical
- Relative Strength Index (RSI)
- ADGM N/A
- CALC 56.52
- Support Level
- ADGM N/A
- CALC $1.86
- Resistance Level
- ADGM N/A
- CALC $2.04
- Average True Range (ATR)
- ADGM 0.00
- CALC 0.14
- MACD
- ADGM 0.00
- CALC 0.05
- Stochastic Oscillator
- ADGM 0.00
- CALC 64.79
About ADGM ADAGIO MEDICAL HOLDINGS INC
Adagio Medical Holdings Inc is an innovator in catheter ablation technologies for the treatment of cardiac arrhythmias. The company focuses on developing cryoablation technologies that create contiguous, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.